The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Pfizer CEO Dr. Albert Bourla was loudly booed during a White House Black History Month event where he was introduced by President Trump.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, ...

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...

Greek-American Pfizer CEO Dr Albert Bourla faced an unwelcoming reception at the White House during an event celebrating ...